Key result
Three daily NovoPen injections linked to improved metabolic control and acceptability in adolescent diabetics.
Why the study?
Does a regimen of three injections per day involving the NovoPen improve metabolic control and patient acceptability in adolescent diabetics?
Does a regimen of three injections per day involving the NovoPen improve metabolic control and patient acceptability in adolescent diabetics?
A three-injection per day regimen using the NovoPen improved metabolic control and patient acceptability in a small cohort of adolescent diabetics over 12 months.
Suggests possible benefit of NovoPen-based thrice-daily insulin in adolescents; hypothesis-generating and should not change practice without further evidence.
A regimen of three injections per day involving the NovoPen (Novo Laboratories Ltd, Basingstoke, Hants, UK) was assessed in eight adolescent diabetics (median age l3.5 years). Six months after the institution of this regimen there was an improvement in metabolic control (assessed by HbA1c measurements) and patient acceptability (assessed by questionnaire). This improvement was maintained for a further six‐month period.
No takes yet. Share an insight, caveat, or question.
Jenkins et al. (1989) studied diabetes (n=8). NovoPen was evaluated on metabolic control (assessed by HbA1c measurements) and patient acceptability. A regimen of three injections per day using the NovoPen improved metabolic control and patient acceptability in 8 adolescent diabetics over 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: